Abivax Unveils Its 2025 Financial Schedule
Abivax SA, a clinical-stage biotechnology company, has revealed its anticipated financial communication calendar for 2025. The company is dedicated to developing innovative therapies that target chronic inflammatory diseases. This exciting announcement highlights the various important dates for financial reporting and meetings that shareholders and interested stakeholders should note.
Key Financial Reporting Dates
The company has lined up several critical dates in 2025 for reporting its financial outcomes. Below are the significant milestones:
March 24, 2025
After the US market closes, Abivax will publish its comprehensive business and financial report for the year ended December 31, 2024. Key documents will include a press release, the Universal Registration Document, and the Annual Report on Form 20-F, ensuring transparency for investors.
June 2, 2025
More updates will follow on June 2, 2025, when the company intends to announce its first-quarter financial results. Like the previous report, this publication will follow the close of the US market, reflecting the company’s commitment to keeping its investors informed.
Annual General Meeting on June 6, 2025
The Annual General Meeting, another vital event in the company's calendar, is set to take place on June 6, 2025. Shareholders are invited to participate in this live meeting, facilitating an opportunity for investors to engage with the company's management.
August 11, 2025
The next financial checkpoint will occur on August 11, 2025, when Abivax will disclose its Half-Year Business and Financial Report for the period ending June 30, 2025. Included in this report will be additional press releases and a Half-Year Financial Report, once again showcasing the company’s ongoing commitment to transparency.
December 15, 2025
The final major event of the year will be the third-quarter financial results announcement on December 15, 2025. This report, also shared after the US market closes, will include findings from the period ending September 30, 2025, along with corresponding updates via press release and the Form 6-K shareholder communication.
About Abivax
Abivax is a pioneering biotechnology firm focused on developing therapeutics that naturally stabilize the immune response in individuals suffering from chronic inflammatory disorders. With operational bases in France and the United States, the company's leading drug candidate, obefazimod (ABX464), is currently undergoing Phase 3 clinical trials aimed at treating those with moderately to severely active ulcerative colitis.
Contact Information
For more details regarding their financial updates or inquiries, interested parties can reach out to Patrick Malloy, Senior Vice President of Investor Relations at Abivax SA. His contact number is +1 847 987 4878, and he can also be reached via email at patrick.malloy@abivax.com.
Frequently Asked Questions
What is the purpose of the financial communications calendar?
The financial communications calendar outlines key reporting dates for investors, allowing stakeholders to stay informed about the company's financial performance.
When will Abivax's Annual General Meeting take place?
The Annual General Meeting is scheduled for June 6, 2025, and will be conducted as a live event.
What is the significance of the report on March 24, 2025?
This report will provide a comprehensive overview of Abivax's business and financial activities for the year ending December 31, 2024.
How often does Abivax plan to release financial results?
Abivax plans to release financial results quarterly, with reports following the close of each significant trading period.
What is obefazimod's role in Abivax's product development?
Obefazimod (ABX464) is Abivax's leading drug candidate, currently in Phase 3 clinical trials to treat ulcerative colitis, demonstrating the company’s commitment to innovative therapeutic solutions.
